Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury
Abstract
Processes and materials are provided for the detection, diagnosis, or determination of the severity of a neurological injury or condition, including traumatic brain injury, multiple-organ injury, stroke, Alzeimer's disease, Parkinson disease and Chronic Traumatic Encephalopathy (CTE). The processes and materials include biomarkers detected or measured in a biological sample such as whole blood, serum, plasma, or CSF. Such biomarkers include Tau and GFAP proteins, their proteolytic breakdown products, brain specific or enriched micro-RNA, and brain specific or enriched protein directed autoantibodies. The processes and materials are operable to detect the presence of absence of acute, subacute or chronic brain injuries and predict outcome for the brain injury.
Claims
exact text as granted — not AI-modified1 . (canceled)
2 . A method for detecting a biomarker, comprising:
contacting Tau or a Tau breakdown product thereof with a sample from a subject suspected of having a traumatic brain injury (TBI); and detecting binding between Tau or the Tau breakdown product and the biomarker in the sample, wherein the biomarker is an autoantibody that binds specifically to Tau or a breakdown product thereof.
3 . The method of claim 2 , wherein the biomarker is an autoantibody that binds specifically to Tau set forth in SEQ ID NO: 11.
4 . The method of claim 2 , wherein the biomarker is an autoantibody that binds specifically to a breakdown product of Tau set forth in SEQ ID NO: 11.
5 . The method of claim 4 , wherein the breakdown product of Tau is formed by cleavage C-terminal to amino acid 25, 44, 129, 157, 229, or 421 of SEQ ID NO: 11.
6 . The method of claim 2 , wherein the sample is blood, serum, plasma, cerebrospinal fluid (CSF), urine, saliva, or tissue.
7 . The method of claim 6 , wherein the sample is blood, plasma, or serum.
8 . The method of claim 7 , wherein the sample is serum.
9 . The method of claim 2 , wherein the binding between the biomarker and Tau or the Tau breakdown product thereof is detected using an enzyme linked immunosorbent assay (ELISA) or a western blot.
10 . The method of claim 9 , wherein the binding between the biomarker and Tau or the Tau breakdown product thereof is detected using an ELISA.
11 . A method, comprising:
contacting a sample obtained from a subject suspected of having a traumatic brain injury (TBI) with Tau or a Tau breakdown product thereof; detecting binding between the biomarker and Tau or the Tau breakdown product thereof; and administering a therapeutic to the subject if binding between the biomarker and Tau or the Tau breakdown product thereof is detected.
12 . The method of claim 11 , wherein the biomarker is an autoantibody that binds specifically to Tau set forth in SEQ ID NO: 11.
13 . The method of claim 11 , wherein the biomarker is an autoantibody that binds specifically to a breakdown product of Tau set forth in SEQ ID NO: 11.
14 . The method of claim 13 , wherein the breakdown product of Tau is formed by cleavage C-terminal to amino acid 25, 44, 129, 157, 229, or 421 of SEQ ID NO: 11.
15 . The method of claim 11 , wherein the sample is blood, serum, plasma, CSF, urine, saliva or tissue.
16 . The method of claim 11 , wherein the sample is blood, plasma, or serum.
17 . The method of claim 11 , wherein the sample is serum.
18 . The method of claim 11 , wherein the binding between the biomarker and Tau or the Tau breakdown product is detected using an enzyme linked immunosorbent assay (ELISA) or a western blot.
19 . The method of claim 11 , wherein the binding between the biomarker and Tau or the Tau breakdown product is detected using an ELISA.Join the waitlist — get patent alerts
Track US2019064188A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.